4470-79-5

Basic information

• Product Name: 17-Hydroxy-21-iodoprogesterone
• Synonyms: 17-Hydroxy-21-iodopregn-4-ene-3,20-dione;17-Hydroxy-21-iodoprogesterone;21-Iodopregn-4-ene-17-ol-3,20-dione;Pregn-4-ene-3,20-dione, 17-hydroxy-21-iodo-;(8R,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-iodoacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS NO: 4470-79-5
• Molecular Formula: C₂₁H₂₉IO₃
• Molecular Weight: 456.36
• Mol File: 4470-79-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 17-Hydroxy-21-iodoprogesterone(CAS DataBase Reference)
• NIST Chemistry Reference: 17-Hydroxy-21-iodoprogesterone(4470-79-5)
• EPA Substance Registry System: 17-Hydroxy-21-iodoprogesterone(4470-79-5)

Safety Data

• Hazardous Substances Data: 4470-79-5(Hazardous Substances Data)

Upstream product

• 152-58-9 Cortexolone 
• 106342-08-9 21-p-toluenesulfonate of 17α,21-dihydroxy-4-pregnene-3,20-dione 
• 68-96-2 17-hydroxyprogesterone 

Downstream Products

• 96112-87-7 17α-Hydroxy-17β-(2-sec-butylamino-thiazolyl-4-yl)-androst-4-en-3-one 
• 640-87-9 cortexolone 21-acetate 
• 93604-95-6 C₃₀H₄₃N₃O₁₄P₂ 
• 68-96-2 17-hydroxyprogesterone 
• 114967-85-0 (17α-Hydroxy-4-pregnene-3,20-dion-21-yl-21-thio)acetic acid 
• 96276-36-7 17β-[2-(4-chloro-anilino)-thiazol-4-yl]-17α-hydroxy-androst-4-en-3-one 
• 96274-83-8 17β-(2-anilino-thiazol-4-yl)-17α-hydroxy-androst-4-en-3-one 
• 96269-26-0 17α-hydroxy-17β-[2-(4-methoxy-anilino)-thiazol-4-yl]-androst-4-en-3-one 
• 96276-35-6 17β-[2-(2-chloro-anilino)-thiazol-4-yl]-17α-hydroxy-androst-4-en-3-one 
• 88934-38-7 17β-(2-amino-thiazol-4-yl)-17α-hydroxy-androst-4-en-3-one 
• 96365-56-9 17α-hydroxy-17β-(2-methylamino-thiazol-4-yl)-androst-4-en-3-one 
• 96274-75-8 17β-(2-cyclohexylamino-thiazol-4-yl)-17α-hydroxy-androst-4-en-3-one 
• 107329-06-6 17β-[2-(2,5-dichloro-anilino)-thiazol-4-yl]-17α-hydroxy-androst-4-en-3-one 
• 107305-52-2 17β-[2-(2,3-dichloro-anilino)-thiazol-4-yl]-17α-hydroxy-androst-4-en-3-one 

Relevant articles and documents

An efficient hemisynthesis of 20- and 21-[13C]-labeled cortexolone: A model for the study of skin sensitization to corticosteroids

A method is described for the synthesis of isotopomers of cortexolone from the commercially available andros-4-ene-3, 17dione. The strategy is based on the use of K13CN for labeling at position 20 and of 13CH 3Mgl, generated in situ, for labeling at position 21. Because of the early introduction of the [13C] labeling, our efforts aimed at reproducible experimental procedures giving high yields with respect to the isotope containing precursors. During the development of this hemisynthesis, we noted that judicious choice of protective groups was essential as this could lead not only to mixtures or unstable intermediates but also influence considerably the output of reactions.

Nucleoside conjugates. 6. Synthesis and comparison of antitumor activity of 1-β-D-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols

Five new P1-(steroid-21-yl)-P2-(1-β-D-arabinofuranosylcytosin-5'-yl)pyrophosphat es (ara-CDP-steroids), five 1-β-D-arabinofuranosylcytosine 5'-O-(alkyl)phosphates (ara-CMP-alkyl esters), and two P1-(alkyl)-P2-(1-β-D-arabinofuranosylcytosin-5'-yl)pyrophosphate (ara-CDP-alkyl esters) have been prepared and evaluated against L1210 lymphoid leukemia in culture and in mice (C3D2F1/J). These include ara-CDP-11-deoxycorticosterone, ara-CDP-cortisone, ara-CDP-corticosterone, ara-CDP-cortexolone, and ara-CDP-prednisone, ara-CMP hexadecyl ester, ara-CMP 1-cyclohexylmethyl ester, ara-CMP 1-adamantylmethyl ester, ara-CMP 2-(1-adamanthyl)ethyl ester, ara-CMP 2-chloroethyl ester, ara-CDP hexadecyl ester, and ara-CDP 1-cyclohexylmethyl ester. The in vitro antitumor results indicated that ara-CDP-steroids were as active as the previously reported ara-CMP-steroids and that ara-CMP and ara-CDP-alkyl esters were less growth inhibiting than ara-CDP-steroids and ara-C. However, the in vivo antitumor results indicated that ara-CDP-steroids were generally less effective than the previous monophosphate derivatives. Among them ara-CDP-corticosterone and the known ara-CDP-cortisol showed greater efficacy than ara-C with ILS value of 152% and 209%, respectively, at the optimal dose of 40 and 80 (mg/kg)/day for 9 days, while that of ara-C was 138% at the optimum dose of 9.2 (mg/kg)/day. Generally, ara-CMP alkyl esters, given ip to the L1210 leukemic mice, were found to be toxic and ineffective. However, ara-CDP hexadecyl ester showed marginal activity (ILS, 38%). These preliminary results support the thesis that the ara-C conjugates of this type may require a lipophilic and naturally occurring moiety for improved efficacy.